• Access To Medicines

Evaluating patient access to rare disease treatments

Influencing and shaping our sector: July - October 2023

The BioIndustry Association (BIA) continued to represent the innovative life science and biotech sector to Ministers and senior policymakers between July and October 2023.

BIA response to DHSC statutory scheme consultation

The BIA has responded to DHSC's consultation on the proposed review of the statutory scheme to control the cost of branded health service medicines.